Persistent fever and destructive arthritis caused by dialysis-related amyloidosis

A case report

Kotaro Matsumoto, MDa, Jun Kikuchi, MD, PhDa, Yuko Kaneko, MD, PhDa, Hidekata Yasuoka, MD, PhDa, Kazuko Suzuki, MD, PhDb, Hirobumi Tokuyama, MD, PhDb, Kaori Kameyama, MD, PhDb, Kunihiro Yamaoka, MD, PhDa, Tsutomu Takeuchi, MD, PhDa,*

Abstract

Rationale: Dialysis-related amyloidosis (DRA) can present rheumatic manifestations in patients on long-term hemodialysis. Typical articular symptoms with DRA involve carpal-tunnel syndrome, effusion in large joints, spondyloarthopathy, or cystic bone lesions, which are usually with non-inflammatory processes.

Patient concerns: A 64-year-old man on hemodialysis for >30 years was admitted because of intermittent fever, polyarthritics, and elevated serum C-reactive protein (CRP) level, which was continuous for 2 years. Several antibiotics were ineffective for 3 months before his admission. On physical examination, joint swelling was observed at bilateral wrists, knees, ankles, and hip joints. Laboratory tests revealed elevation of serum inflammatory markers and β2-microglobulin (β2-MG). Synovial fluid showed predominant infiltration of polymorphonuclear leukocytes and the increase of β2-MG level.

Diagnosis: Significant deposition of β2-MG with inflammatory cell infiltration was found in biopsied samples from synovium, skin, and ileum.

Interventions: We decided to switch to the hemodialysis column with membrane that can effectively absorb β2-MG in circulation.

Outcomes: The relief of symptoms and a decrease of CRP level by changing the membrane lead to the final diagnosis of DRA.

Lessons: Our case demonstrates that DRA arthropathy can be inflammatory and destructive, and also develop systemic inflammatory signs and symptoms. In such cases, aggressive absorption of β2-MG in circulation might help the amelioration of symptoms.

Abbreviations: β2-MG = β2-microglobulin, β2MG-AGE = β2-microglobulin modified by advanced glycation end products, Aβ2M = β2-microglobulin amyloid, CRP = C-reactive protein, CT = computed tomography, DRA = dialysis-related amyloidosis, FDG = fluorodeoxyglucose, MRI = magnetic resonance imaging, PES = polyethersulfone, STIR = T2-weighted short-tau inversion recovery.

Keywords: β2-microglobulin, β2-microglobulin modified by advanced glycation end products, dialysis-related amyloidosis, fever of unknown origin, long-term hemodialysis

1. Introduction

Amyloidosis is a condition characterized by systemic extracellular deposition of an abnormal fibrous protein, amyloid. Amyloid fibrils are formed by normal soluble proteins, which assemble to form insoluble fibers that are resistant to degradation.1 One of amyloid fibrils, β2-microglobulin amyloid (Aβ2M), are made of misfolded β2-microglobulin (β2-MG) and extracellular matrix.2–4 β2-MG in serum is usually excreted by glomerular filtration, but in patients with long-standing end-stage kidney disease who are on hemodialysis, serum β2-MG levels can be increased to up to 60 times those in normal individuals.5 Since the level of β2-MG is above the capacity of the dialyzer,6 this leads to the systemic deposition of Aβ2M, resulting in dialysis-related amyloidosis (DRA).

The typical manifestation of DRA includes carpal-tunnel syndrome, non-inflammatory effusion in large joints, spondyloarthropathy, and cystic bone lesions. However, inflammatory symptoms are usually rare and only a few cases with fever or inflammatory arthritis have been reported.6–8

Here, we report a unique case of DRA with systemic inflammation who developed persistent fever and erosive arthritis, which was improved by efficient hemofiltration of β2-MG.

2. Case presentation

A 64-year-old Japanese man on hemodialysis for over 30 years was admitted to our hospital in 2016 with intermittent fever, polyarthritics, and elevated C-reactive protein (CRP). He was diagnosed as end-stage kidney disease due to nephrosclerosis in...
1984, and hemodialysis was initiated in 1985. He underwent bilateral carpal-tunnel syndrome surgery in 2013. In 2015, he started to feel polyarticular pain with stiffness of his bilateral shoulders, knees, and also back pain. These manifestations were gradually exacerbated. The dull pain persisted almost whole day, and increased by flexing. He did not realize the morning stiffness. Three months prior to admission, he developed fever, especially following dialysis. Several antibiotics such as ceftriaxone and levofloxacin were administered for a few weeks, but showed no effects. No other symptoms of cough, appetite loss, weight loss, or night sweats were present.

On admission, physical examination revealed a normal blood pressure of 120/70mmHg and body temperature of 39.0°C. His bilateral wrists, knees, ankles, and hip joints were swollen with tenderness. Flexion contracture was also observed in both hands and knees. Auscultation of heart sounds showed irregular rhythm, normal S1 and S2, and Levine III/IV systolic murmurs on from 2nd to 4th left sternal borders due to moderate to severe tricuspid regurgitation. There were no redness or tenderness on his vascular graft. No other abnormal findings upon examination of the eyes, lymph nodes, lungs, abdomen, neurological systems, and skin were tested.

Laboratory studies of blood showed an elevated CRP (9.22 mg/dL, normal range: <0.35 mg/dL), erythrocyte sedimentation rate (124 mm/h, normal range: <15 mm/h), and matrix metalloproteinase-3 (>1200 ng/mL, normal range: 35.2–123.8 ng/mL). The serum β2-MG level was extremely high (25.68 mg/L, normal range: 0.9–1.7 mg/L). Total protein was 6.5g/dL and no monoclonal M peak or abnormal κ/λ ratios were found (Table 1). Arthrocentesis was also examined and the cell count in his right knee was 9700/µL with predominating polymorphonuclear leukocytes. Gram staining and bacterial culture were negative, but calcium pyrophosphate dihydrate (CPPD) was detected. Moreover, β2-MG in the synovial fluid was detected with a higher concentration (34.97 mg/L) than that in peripheral blood. Computed tomography (CT) of bilateral shoulder joints, humeri, and hip joints showed severely damaged lytic bone lesions surrounded by low density soft tissue (Fig. 1A). A T2-weighted short-tau inversion recovery (STIR) magnetic resonance imaging (MRI) of the right knee joint showed a low-intensity area with fluid collection (Fig. 1B). Positron emission tomography-CT with [18F]fluorodeoxyglucose (FDG) demonstrated abnormal FDG uptake in the large joints (standardized uptake value max: 7.6) as shown in Fig. 1C. These findings did indicate existence of destructive arthritis and abnormal periarticular deposition. Considering malignant tumor or infectious disease, we conducted biopsies from his right knee synovium, right thigh skin, and subcutaneous collagen tissue and iliac mucosal tissue. No evidence of heart amyloidosis was detected by transthoracic echocardiography. Although it was difficult to rule out clearly the possibility of symptomatic pseudogout, histological findings did not support the diagnosis. According to the literature, asymptomatic CPPD crystals in joint fluids could be presented in elderly patients.[9] Multiple myeloma was the first differential diagnosis considering the multiple osteolytic lesion, but the examinations made the possibilities less likely. Malignancies or infectious diseases, which was considered from multiple sites of positive uptake in PET-CT, were denied by several biopsies. Bacterial infection was also denied by negative blood or synovial fluid cultures, β-D glucan, or interferon-gamma release assay. Finally, dialysis-related Aβ2M amyloidosis was suspected to cause fever.

Dialyzer used for hemodialysis was polyethersulfone (PES) membrane, which has low efficiency of urea removal rate of 53% and Kt/V of 0.9, suggesting that filtration efficiency of β2-MG of hemodialysis of the patient was also relatively low. Thus, we switched to the polymethyl methacrylate column that has a superior efficiency of Aβ2M removal.[10] In addition, the time of one dialysis session was extended from 3.5 to 4 hours. After the dialysis with the new column was started from August 2016, serum β2-MG, dry weight, and cardio-thoracic ratio of chest x-ray gradually decreased. Then, we finally confirmed normalization of the high levels of inflammatory marker and fever with his articular symptoms improved in January 2017 (Fig. 3). Considering the several months of delay from treatment intervention to amelioration of the disease state matched to DRA, rather than

**Table 1**

| Laboratory findings |
|---------------------|
| **Hematology** |
| WBC, /µL | 8100 |
| Neutrophils, % | 81 |
| Lymphocytes, % | 10 |
| Monocytes, % | 7 |
| Eosinophils, % | 2 |
| Hemoglobin, g/dL | 9.7 |
| Hematocrit, % | 32.6 |
| Platelet, ×10^9/µL | 14.2 |
| **Biochemistry** |
| Total protein, g/dL | 6.5 |
| Albumin, g/dL | 2.7 |
| Bilirubin, total, mg/dL | 0.4 |
| BUN, mg/dL | 65.7 |
| Creatinine, mg/dL | 7.99 |
| Urea acid, mg/dL | 3.0 |
| AST, U/L | 19 |
| ALAT, U/L | 8 |
| ALP, U/L | 313 |
| Sodium, mEq/L | 137.7 |
| Potassium, mEq/L | 4.3 |
| Chloride, mEq/L | 100 |
| CRP, mg/dL | 9.22 |
| Ferritin, nm/L | 353 |
| Calcium, mg/dL | 8.6 |
| Phosphate, mg/dL | 5.9 |
| Intact-parathyroid hormone, pg/mL | 101 |
| **Immunology** |
| IgG, mg/dL | 1617 |
| IgA, mg/dL | 518 |
| IgM, mg/dL | 63 |
| Antinuclear antibody | Negative |
| MMP-3, ng/mL | >1200 |
| β2-MG, mg/L | 25.68 |

β2-MG = β2-microglobulin, ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BUN = blood urea nitrogen, CRP = C-reactive protein, IgA = immunoglobulin A, IgG = immunoglobulin G, IgM = immunoglobulin M, MMP-3 = matrix metalloproteinase-3, WBC = white blood cell.
pseudogout. Taken together of these reasons, we thought the trigger of inflammation was attributed to deposition of $\text{A}_\text{B}2\text{M}$.

3. Discussion

We showed the case with DRA presenting fever and erosive arthritis caused by the massive, long-term deposition of $\text{A}_\text{B}2\text{M}$, suggesting that DRA could cause a systemic inflammatory response and destructive joint inflammation.

The risk factors that promote DRA are long-term hemodialysis treatment, elderly initiation of hemodialysis, lack of remaining renal function, and a dialysis with low filtration efficiency.\cite{11,12} The deposition of $\text{A}_\text{B}2\text{M}$ occurs mainly in bone, cartilage, and synovial membrane, and nerve compression symptoms such as carpal-tunnel syndrome, bone cyst, and bone destruction are often developed. The frequency of joint restriction and effusions in large and medium size joints rises along with the duration of hemodialysis.\cite{13} Although $\text{A}_\text{B}2\text{M}$ can also deposit in various organs and result in multiple organ disorders, gastrointestinal and cardiac involvement is rare in DRA.\cite{14,15} Our case had a long-term usage of conventional dialyzer, which had relatively low filtration efficiency but convenient and low cost, resulting in developing intensive joint symptoms, but without skin eruption or abdominal symptoms despite the microscopic deposit of $\text{A}_\text{B}2\text{M}$ in the skin and ileum, and no cardiac involvement.

As mentioned above, polymethylmethacrylate dialysis membranes possibly improve his arthritis due to good filtration efficiency of $\text{B}_2\text{-MG}$. However, they remove solutes of circulating cytokines and some cationic compounds as well as $\text{B}_2\text{-MG}$.\cite{16} We cannot deny another hypothesis that polymethylmethacrylate dialysis membranes improve inflammation by removing inflammatory compounds other than $\text{B}_2\text{-MG}$.

The question of whether DRA might cause fever remains controversial.\cite{17,18} In the amyloid plaques of DRA patients, $\text{B}_2\text{-MG}$ is modified by advanced glycation end products ($\text{B}_2\text{MG-AGE}$).\cite{19,20} In uremic patients, increased 3-deoxyglucosone, a

Figure 1. Images of CT, MRI, and 18F-FDG PET of the patients. (A) A representative image of computed tomography of right shoulder. Damaged shoulders (shown by arrows) surrounded by low-density soft tissue was shown. (B) T2-STIR magnetic resonance images of the right knee. A low-intensity area (shown by thin arrow) representing fluid collection. (C) Images of 18F-FDG positron-emission computed tomography. FDG uptake in the large joints was shown with arrows. CT = computed tomography, DRA = dialysis-related amyloidosis, FDG = fluorodeoxyglucose, MRI = magnetic resonance imaging, STIR = T2-weighted short-tau inversion recovery.
highly reactive dicarbonyl compound, may promote the AGE modification of β2-MG,[21] and β2MG-AGE may lead to an inflammatory response and the recruitment of monocytes and macrophages around amyloid deposits. β2MG-AGE is biologically active and interacts with mononuclear phagocytes and synovial fibroblasts through the receptors of advanced glycation end products, stimulating the release of proinflammatory cytokines for monocytes or macrophages.[22] The fever often seen following dialysis, as in our case, may be explained in part by induced cytokine production and complement activation due to the dialysis treatment.[23] The activation of inflammatory cascades has been attributed to the exposure of blood to dialysis membranes or the back leakage of lipopolysaccharide through the dialysis membranes.[24]

Although some previous cases with Aβ2M amyloidosis with systemic inflammation were reported to need glucocorticoid therapy,[6] our case was treatable by dialyzer membrane exchange and an extended dialysis time, suggesting that dialysis efficiency is important in the treatment and prevention of DRA.

4. Conclusions

Our case highlights that DRA can lead to systemic inflammation and destructive inflammatory arthritis. Physicians should be aware of DRA as a cause of fever in a case with a long history of dialysis and a high level of serum β2-MG. Aggressive absorption of β2-MG in circulation might help the amelioration of symptoms in such cases.

References

[1] Rowe IF. Amyloid arthropathy. Ann Rheum Dis 1985;44:727–8.
[2] Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun 1985;129:701–6.
[3] Gorevic PD, Casey TT, Stone WJ, et al. Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest 1985;76:2425–9.
[4] Koch KM. Dialysis-related amyloidosis. Kidney Int 1992;41:1416–29.
[5] Scarponi R, Ricardi M, Albertazzi V. Secondary amyloidosis in autoimmune diseases and the role of inflammation in renal damage. World J Nephrol 2016;5:66–75.
[6] Ishii T, Ohtake T, Oda O, et al. A case of fever of unknown origin (FUO) caused by dialysis associated amyloidosis (DRA) in a patient on long term hemodialysis therapy. J Jpn Soc Dial Ther 2007;40:1057–62.
[7] Nakano T, Nagae H, Murakami N, et al. Fever associated with severe dialysis-related amyloidosis. CEN Case Rep 2012;1:112–6.
[8] Sato K, Onubu S, Orie S, et al. Characteristics of chronic kidney disease patients admitted to our hospital to investigate the cause of fever. J Jpn Soc Dial Ther 2008;41:317–22.
[9] Hamilton E, Patrício M, Hornby J, et al. Synovial fluid calcium pyrophosphate dihydrate crystals and alizarin red positivity: analysis of 3000 samples. Br J Rheumatol 1990;29:101–4.
[10] Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010–9.
[11] Clanciolo G, Coli L, La Manna G, et al. Is beta2-microglobulin-related amyloidosis of hemodialysis patients a multifactorial disease? A new pathogenetic approach. Int J Artif Organs 2007;30:864–78.
[12] Fry AC, Singh DK, Chandna SM, et al. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif 2007;25:295–302.
[13] Brancaccio D, Cozzolino M, Gallieni M. Dialysis amyloidosis: clinical aspects and therapeutic approach. Nephrol Dial Transplant 1996;11 (Suppl):102–5.
[14] Ikegaya N, Kobayashi S, Hishida A, et al. Colonic dilatation due to dialysis-related amyloidosis. Am J Kidney Dis 1995;25:807–9.
[15] Hurst NP, van den Berg R, Disney A, et al. ‘Dialysis related arthropathy’: a survey of 95 patients receiving chronic haemodialysis with special reference to beta 2 microglobulin related amyloidosis. Ann Rheum Dis 1989;48:409–20.
[16] Ausella F, Vigilante M, Gesuete A. Review: the effect of polymethylmethacrylate dialysis membranes on uraemic pruritus. NDT Plus 2010;3 (Suppl):10–11.
[17] Muñoz-Gómez J, Gómez-Pérez R, Solé-Arques M, et al. Synovial fluid examination for the diagnosis of synovial amyloidosis in patients with chronic renal failure undergoing haemodialysis. Ann Rheum Dis 1987;46:324–6.
[18] Kiss E, Keusch G, Zanetti M, et al. Dialysis-related amyloidosis revisited. AJR Am J Roentgenol 2005;185:1460–7.
[19] Miyata T, Oda O, Inagi R, et al. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243–52.
[20] Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994;93:521–8.
[21] Niwa T, Tsukushi S. 3-deoxyglucosone and AGEs in uremic complications: inactivation of glutatione peroxidase by 3-deoxyglucosone. Kidney Int Suppl 2001;78:S37–41.
[22] Hou FF, Jiang JP, Guo JQ, et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 2002;13:1296–306.
[23] Schaeffer J, Floge J, Ehlerding G, et al. Pathogenetic and diagnostic aspects of dialysis-related amyloidosis. Nephrol Dial Transplant 1993;10 (Suppl):4–8.
[24] da Costa JA, Ikizler TA. Inflammation and insulin resistance as novel mechanisms of wasting in chronic dialysis patients. Semin Dial 2009;22:632–7.